WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced the appointment of Gregory Perry to the Company’s Board of Directors and Chair of its Audit Committee.
“We are pleased to welcome Greg to our board of directors and chair of our audit committee. Greg brings a wealth of business, strategic and financial expertise gained during his accomplished career in the biotech industry. We look forward to benefitting from his guidance as the company matures and we continue to advance toward commercialization,” said Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals.
Mr. Perry has served as Audit Committee Chair at Merus N.V. since 2016. He served as Chief Financial and Administrative Officer at Aegerion Pharmaceuticals Inc. from 2015 until the company’s merger with Novelion Therapeutics Inc., after which he served as Chief Financial and Administrative Officer at Novelion until 2017. Prior to joining Aegerion, Mr. Perry held the role of Chief Financial and Business Officer at Eleven Biotherapeutics, Inc. from 2014-2015. He was a member of the Board of Directors, Audit Committee Chair and Compensation Committee Member at Ocata Therapeutics, Inc. from 2011 until the company was acquired by Astellas Pharma Inc. in 2016. Prior to that, he served as Senior Vice President and Chief Financial Officer at ImmunoGen, Inc. from 2009 until he was promoted in 2011 to Executive Vice President and Chief Financial Officer, a role that he held until 2013. From 2002-2008, Mr. Perry served as Chief Financial Officer at a series of biotechnology companies including Elixir Pharmaceuticals, Inc., Domantis Ltd., Transkaryotic Therapies, Inc. and PerkinElmer Inc. Mr. Perry holds a Bachelor of Arts Degree in Economics and Political Science from Amherst College.
“This is an exciting time to join Kala’s Board of Directors and I am eager to work with the company as it continues to grow and develop innovative treatments for patients with eye diseases,” said Mr. Perry.
About Kala Pharmaceuticals, Inc.
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYS™ (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which the FDA has accepted for review Kala’s NDA submission and has established a PDUFA target action date of August 24, 2018, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties including statements regarding the development and regulatory status of the company's product candidates, including INVELTYS™ (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company’s strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of various risks and uncertainties including, but not limited to: whether our NDA for INVELTYS will be approved by its PDUFA target action date or at all; uncertainties inherent in the availability and timing of data from ongoing clinical trials; expectations for regulatory approvals to conduct trials or to market products; whether the Company’s cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the availability or commercial potential of the Company’s product candidates; and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, discussed in the "Risk Factors" section of the Company’s most recently filed Quarterly Report on Form 10-Q and other filings the Company makes with the Securities and Exchange Commission. These forward-looking statements represent the Company’s views as of the date of this release and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company does not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.